Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review
Frontiers in Immunology · 13.12.2024 · 15
DOI: 10.3389/fimmu.2024.1513421 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 13.12.2024. Verfasst von Lucía Serrano García und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valencia…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 335 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of progesterone and estrogen receptors and low (or absent) HER2 expression. TNBC accounts for 15-20% of all breast cancers. It is associated with younger age, a higher mutational burden, and an increased risk of recurrence and mortality. Standard treatment for TNBC primarily relies on cytotoxic agents, such as taxanes, anthracyclines, and platinum compounds for both early and advanced stages of the disease. Several targeted therapies, including bevacizumab and sunitinib, have failed to demonstrate significant clinical benefit in TNBC. The emergence of immune checkpoint inhibitors (ICI) has revolutionized cancer treatment. By stimulating the immune system, ICIs induce a durable anti-tumor response across various solid tumors. TNBC is a particularly promising target for treatment with ICIs due to the higher levels of tumor-infiltrating lymphocytes (TIL), increased PD-L1 expression, and higher mutational burden, which generates tumor-specific neoantigens that activate immune cells. ICIs administered as monotherapy in advanced TNBC yields only a modest response; however, response rates significantly improve when ICIs are combined with cytotoxic agents, particularly in tumors expressing PD-L1. Pembrolizumab is approved for use in both early and advanced TNBC in combination with standard chemotherapy. However, more research is needed to identify more potent biomarkers, and to better elucidate the synergism of ICIs with other targeted agents. In this review, we explore the challenges of immunotherapy in TNBC, examining the mechanisms of tumor progression mediated by immune cells within the tumor microenvironment, and the signaling pathways involved in both primary and acquired resistance. Finally, we provide a comprehensive overview of ongoing clinical trials underway to investigate novel immune-targeted therapies for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
- Grupo Oncología Traslacional, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-Centro de Estudios Universitarios (CEU), Alfara del Patriarca, Spain.
- Medica Scientia Innovation Research (MEDSIR), Oncoclínicas & Co., Jersey City, NJ, United States.
- Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain.
- International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
- Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.
Zitieren
APA
Serrano García, L., Jávega, B., Llombart Cussac, A., Gión, M., Pérez-García, J. M., Cortés, J., & Fernández-Murga, M. L. (2024). Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1513421
Vancouver
Serrano García L, Jávega B, Llombart Cussac A, Gión M, Pérez-García JM, Cortés J, et al. Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1513421
BibTeX
@article{SerranoGarca2024,
author = {Serrano García, Lucía and Jávega, Beatriz and Llombart Cussac, Antonio and Gión, María and Pérez-García, José Manuel and Cortés, Javier and Fernández-Murga, María Leonor},
title = {Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review},
journal = {Frontiers in Immunology},
year = {2024},
volume = {15},
doi = {10.3389/fimmu.2024.1513421}
}
EUVIMED